A leading pediatricians’ group is urging doctors to use evidence and their best judgement in prescribing “off-label” drugs, a common practice with kids with autism and other disabilities.
As more people become eligible for Medicaid, experts say accessing psychiatrists, psychologists and other professionals often relied on by those with disabilities may be difficult.
For the first time in 15 years, a major psychiatric organization is updating its practice guidelines for treating kids and adolescents with autism.
Despite a heavy emphasis on expanded screening for autism, a new study suggests that little is known about whether such efforts are leading to earlier diagnosis and treatment.
A new federally-funded review of thousands of studies finds that there are more than two dozen autism interventions worthy of being called “evidence-based.”
A first-of-its-kind blood test that can help diagnose intellectual disabilities and developmental delays in children is getting the go-ahead from the FDA.
A little remarked upon requirement in the health law expands treatments for those with developmental disabilities. But experts are concerned that insurers may find ways to skirt the new rule.
Many parents are turning to unproven treatments to help their kids with autism and other developmental delays, a new study finds, including some methods that carry serious risks.
A revamped screening tool that relies on parents answering just 20 questions is far more accurate than previous assessments at helping flag young kids at risk for autism, researchers say.
A therapy that uses play to teach children with autism to tolerate sound, touch and other potentially-challenging sensory experiences can be beneficial, new research suggests.
New evidence suggests that a nasal spray of a naturally-occurring hormone may help improve socialization among children with autism.
Autism can be detected in infants as young as 2 months by tracking their eye movements, researchers say, marking the earliest signs of the developmental disorder ever observed.
One of the world’s largest drugmakers will pay to settle allegations that it marketed powerful psychiatric drugs to treat kids with developmental disabilities and for other unapproved uses.
The new health care law requires coverage of therapies that help people with disabilities acquire speech, mobility and other skills, but what that will mean in practice remains murky.
Despite limited evidence supporting the practice, researchers say nearly two-thirds of children with autism are taking at least one psychotropic drug.